JP2008519840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519840A5 JP2008519840A5 JP2007541294A JP2007541294A JP2008519840A5 JP 2008519840 A5 JP2008519840 A5 JP 2008519840A5 JP 2007541294 A JP2007541294 A JP 2007541294A JP 2007541294 A JP2007541294 A JP 2007541294A JP 2008519840 A5 JP2008519840 A5 JP 2008519840A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutical composition
- alkyl group
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- -1 cyclic amine Chemical group 0.000 claims 20
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- OWITVSDXHSDEJK-UHFFFAOYSA-N C1(=CC=CC=C1)C(C(CN1CCCC1)NC(CCCCCCCC)=O)O Chemical compound C1(=CC=CC=C1)C(C(CN1CCCC1)NC(CCCCCCCC)=O)O OWITVSDXHSDEJK-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 1
- UJZMKBUINIZAQA-UHFFFAOYSA-N N-(1-hydroxy-1-phenyl-3-pyrrolidin-1-ylpropan-2-yl)octanamide Chemical compound C=1C=CC=CC=1C(O)C(NC(=O)CCCCCCC)CN1CCCC1 UJZMKBUINIZAQA-UHFFFAOYSA-N 0.000 claims 1
- 206010038468 Renal hypertrophy Diseases 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960004580 glibenclamide Drugs 0.000 claims 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
- 108091005995 glycated hemoglobin Proteins 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 201000008627 kidney hypertrophy Diseases 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 229960000698 nateglinide Drugs 0.000 claims 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960002354 repaglinide Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62644804P | 2004-11-10 | 2004-11-10 | |
| PCT/US2005/040596 WO2006053043A2 (en) | 2004-11-10 | 2005-11-09 | Methods of treating diabetes mellitus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012225142A Division JP2013032377A (ja) | 2004-11-10 | 2012-10-10 | 糖尿病の処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008519840A JP2008519840A (ja) | 2008-06-12 |
| JP2008519840A5 true JP2008519840A5 (enExample) | 2009-01-08 |
Family
ID=35965895
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007541294A Withdrawn JP2008519840A (ja) | 2004-11-10 | 2005-11-09 | 糖尿病の処置方法 |
| JP2012225142A Pending JP2013032377A (ja) | 2004-11-10 | 2012-10-10 | 糖尿病の処置方法 |
| JP2014152732A Expired - Fee Related JP5837657B2 (ja) | 2004-11-10 | 2014-07-28 | 糖尿病の処置方法 |
| JP2015134366A Pending JP2015193638A (ja) | 2004-11-10 | 2015-07-03 | 糖尿病の処置方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012225142A Pending JP2013032377A (ja) | 2004-11-10 | 2012-10-10 | 糖尿病の処置方法 |
| JP2014152732A Expired - Fee Related JP5837657B2 (ja) | 2004-11-10 | 2014-07-28 | 糖尿病の処置方法 |
| JP2015134366A Pending JP2015193638A (ja) | 2004-11-10 | 2015-07-03 | 糖尿病の処置方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8003617B2 (enExample) |
| EP (1) | EP1811991B1 (enExample) |
| JP (4) | JP2008519840A (enExample) |
| BR (1) | BRPI0517701A8 (enExample) |
| CA (1) | CA2586761A1 (enExample) |
| WO (1) | WO2006053043A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2586761A1 (en) | 2004-11-10 | 2006-05-18 | Genzyme Corporation | Methods of treating diabetes mellitus |
| EP2032134B1 (en) * | 2006-05-09 | 2015-06-24 | Genzyme Corporation | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
| US20100048714A1 (en) * | 2006-06-19 | 2010-02-25 | University Of Utah Research Foundation | Methods and Compositions Related to Inhibition of Ceramide Synthesis |
| US8304447B2 (en) * | 2007-05-31 | 2012-11-06 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| KR20160085917A (ko) * | 2007-10-05 | 2016-07-18 | 젠자임 코포레이션 | 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법 |
| WO2010014554A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| US8309593B2 (en) | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| WO2010091164A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| WO2010091104A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| PL3133070T3 (pl) | 2009-11-27 | 2020-01-31 | Genzyme Corporation | Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta |
| MY173998A (en) | 2011-03-18 | 2020-03-03 | Genzyme Corp | Glucosylceramide synthase inhibitors |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| CN108658970A (zh) | 2013-03-15 | 2018-10-16 | 建新公司 | 制备葡萄糖基神经酰胺合酶抑制剂的方法 |
| JO3713B1 (ar) | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
| WO2014150043A1 (en) | 2013-03-15 | 2014-09-25 | Concert Pharmaceuticals Inc. | Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase |
| TWI690511B (zh) | 2013-09-20 | 2020-04-11 | 美商拜奧馬林製藥公司 | 用於治療疾病之葡萄糖苷基腦醯胺（ｇｌｕｃｏｓｙｌｃｅｒａｍｉｄｅ）合成酶抑制劑 |
| WO2015059679A1 (en) * | 2013-10-25 | 2015-04-30 | Dr. Reddy's Laboratories Limited | Improved process for the preparation of eliglustat |
| MX376685B (es) | 2013-10-29 | 2025-03-07 | Biomarin Pharm Inc | Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3-carboxamida como inhibidores de glucosilceramida sintasa. |
| US9758044B2 (en) * | 2014-10-02 | 2017-09-12 | Ford Global Technologies, Llc | Bus leakage resistance estimation for electrical isolation testing and diagnostics |
| KR101711706B1 (ko) * | 2014-11-20 | 2017-03-02 | 주식회사 엘지화학 | 공통 모드 노이즈 시뮬레이터 |
| US10227312B2 (en) | 2015-03-11 | 2019-03-12 | Biomarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
| WO2020026471A1 (ja) * | 2018-07-31 | 2020-02-06 | 株式会社親広産業 | グルコース消費促進剤および解糖系促進剤 |
| PT3920912T (pt) | 2019-02-04 | 2025-09-09 | Genzyme Corp | Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs) |
| WO2021096238A1 (en) | 2019-11-15 | 2021-05-20 | Yuhan Corporation | Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
| KR20210059633A (ko) | 2019-11-15 | 2021-05-25 | 주식회사유한양행 | 신규의 1,2,3,4-테트라하이드로나프탈렌 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물 |
| EP4100009A1 (en) | 2020-02-03 | 2022-12-14 | Genzyme Corporation | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| CA3186766A1 (en) | 2020-07-24 | 2022-01-27 | Danielle Combessis | Pharmaceutical compositions comprising venglustat |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1555654A (en) * | 1977-06-25 | 1979-11-14 | Exxon Research Engineering Co | Agricultural burner apparatus |
| US4065562A (en) * | 1975-12-29 | 1977-12-27 | Nippon Shinyaku Co., Ltd. | Method and composition for reducing blood glucose levels |
| NO154918C (no) * | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
| GB2020278B (en) * | 1978-05-03 | 1983-02-23 | Nippon Shinyaku Co Ltd | Moranoline dervitives |
| JPS568318A (en) | 1979-06-28 | 1981-01-28 | Janssen Pharmaceutica Nv | Non oral long acting composition of haloperidol and bromperidol derivative |
| GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| EP0144290A3 (de) | 1983-12-01 | 1987-05-27 | Ciba-Geigy Ag | Substituierte Aethylendiaminderivate |
| US5041441A (en) * | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
| JPH0416856A (ja) | 1990-05-10 | 1992-01-21 | Canon Inc | 正帯電性非磁性トナー |
| US5302609A (en) * | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
| US5399567A (en) * | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| US5707649A (en) * | 1993-08-13 | 1998-01-13 | Seikagaku Corporation | Agent for treating neuronal diseases |
| ATE195944T1 (de) * | 1994-02-02 | 2000-09-15 | Liposome Co Inc | Pharmazeutisch wirksame verbindungen und liposome und verfahren zu deren herstellung |
| WO1995034530A1 (en) | 1994-06-10 | 1995-12-21 | Seikagaku Corporation | 2-acylaminopropanol compound and medicinal composition |
| US5916911A (en) * | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
| WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20030073680A1 (en) * | 1995-09-20 | 2003-04-17 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6255336B1 (en) * | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| NO965193L (no) * | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| JP3993908B2 (ja) | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
| JP4140984B2 (ja) | 1995-12-20 | 2008-08-27 | 生化学工業株式会社 | 分化誘導作用を有する薬剤 |
| US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
| JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
| JP4176170B2 (ja) | 1997-06-06 | 2008-11-05 | 生化学工業株式会社 | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 |
| US6222619B1 (en) * | 1997-09-18 | 2001-04-24 | University Of Utah Research Foundation | Diagnostic device and method |
| US6465488B1 (en) * | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| ES2285852T3 (es) * | 1998-07-27 | 2007-11-16 | Johns Hopkins University | Compuestos de diamino-propanol para el tratamiento de la isquemia. |
| US6610703B1 (en) * | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
| EP1384719A1 (en) | 1999-07-09 | 2004-01-28 | The Regents of The University of Michigan | Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections |
| EP1196406A1 (en) * | 1999-07-09 | 2002-04-17 | The Regents of the University of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| JP5009459B2 (ja) | 1999-12-06 | 2012-08-22 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
| US6407064B2 (en) | 1999-12-06 | 2002-06-18 | Seikagaku Corporation | Aminoalcohol derivative and medicament comprising the same |
| US6235737B1 (en) * | 2000-01-25 | 2001-05-22 | Peter Styczynski | Reduction of hair growth |
| WO2001080852A1 (en) | 2000-04-19 | 2001-11-01 | Borody Thomas J | Compositions and therapies for hyperlipidaemia-associated disorders |
| JP2005506949A (ja) | 2000-12-20 | 2005-03-10 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | ケモカイン受容体の調節剤としてのジアミン |
| JP2004523509A (ja) | 2000-12-29 | 2004-08-05 | ワイス | ベンゾ〔ｇ〕キノリン−３−カルボニトリルの置換体およびベンゾ〔ｇ〕キナゾリンの置換体の位置選択的調製方法 |
| US20020198240A1 (en) * | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
| CA2434028C (en) * | 2001-01-10 | 2010-11-09 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US7148251B2 (en) * | 2001-01-10 | 2006-12-12 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20040260099A1 (en) * | 2001-01-10 | 2004-12-23 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| EP2266968B1 (en) | 2001-07-16 | 2013-01-09 | Genzyme Corporation | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
| AU2002348261A1 (en) * | 2001-11-26 | 2003-06-10 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
| GB0229931D0 (en) * | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| WO2003057874A1 (fr) * | 2001-12-28 | 2003-07-17 | Sumitomo Pharmaceuticals Company, Limited | Marqueurs de maladies pour maladies renales et leur utilisation |
| DE60303009T2 (de) | 2002-01-22 | 2006-07-13 | Warner-Lambert Co. Llc | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one |
| EP1336411A1 (en) | 2002-02-14 | 2003-08-20 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases |
| JP2003238410A (ja) * | 2002-02-21 | 2003-08-27 | Seibutsu Yuki Kagaku Kenkyusho:Kk | インスリン抵抗性解除剤 |
| US6916802B2 (en) * | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| US20060217560A1 (en) * | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| GEP20084499B (en) | 2002-07-17 | 2008-10-10 | Biogen Idec Inc | USE OF INTERFERON-ß FOR TREATMENT OF RENAL FAILURE |
| EP1534676B1 (en) | 2002-07-17 | 2012-09-12 | Actelion Pharmaceuticals Ltd. | Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
| AU2003225670A1 (en) | 2003-02-28 | 2004-09-28 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
| GB0313678D0 (en) * | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compounds |
| ATE491451T1 (de) | 2003-10-29 | 2011-01-15 | Genzyme Corp | N-(5-adamantane-1-yl-methoxy- pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz |
| EP1528056A1 (en) | 2003-10-29 | 2005-05-04 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
| AU2004308966A1 (en) | 2003-12-23 | 2005-07-14 | Musc Foundaton For Research Development | Methods and compositions for the prevention and treatment of inflammatory diseases or conditions |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| EP1576894A1 (en) * | 2004-03-16 | 2005-09-21 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome |
| JP5154218B2 (ja) * | 2004-03-16 | 2013-02-27 | ネーデルランドセ オルガニサティエ フォール トエゲパスト−ナトールヴェテンシャッペリク オンデルゾエク ティエヌオー | ２型糖尿病、インスリン抵抗性及びメタボリック症候群の治療及び予防においてスフィンゴ脂質を使用する方法 |
| AU2005240714B2 (en) | 2004-05-07 | 2011-07-07 | Merck Patent Gmbh | GM3 synthase as a therapeutic target in microvascular complications of diabetes |
| US20090111812A1 (en) | 2004-06-14 | 2009-04-30 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
| AU2005277186A1 (en) * | 2004-08-20 | 2006-03-02 | The Johns Hopkins University | Methods for treatment of angiogenesis |
| CA2586761A1 (en) | 2004-11-10 | 2006-05-18 | Genzyme Corporation | Methods of treating diabetes mellitus |
| CN101151248B (zh) | 2005-01-26 | 2012-06-20 | 阿勒根公司 | 具有镇痛活性和/或免疫刺激物活性的3-芳基-3-羟基-2-氨基丙酸酰胺类、3-杂芳基-3-羟基-2-氨基丙酸酰胺类以及相关化合物 |
| US8389472B2 (en) | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| EP2032134B1 (en) | 2006-05-09 | 2015-06-24 | Genzyme Corporation | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
| WO2008011478A2 (en) | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| WO2008011487A2 (en) | 2006-07-19 | 2008-01-24 | Allergan, Inc. | L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain |
| GB0614947D0 (en) | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
| TWI389895B (zh) | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| US20100239551A1 (en) | 2007-02-09 | 2010-09-23 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| US8304447B2 (en) * | 2007-05-31 | 2012-11-06 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| KR20160085917A (ko) | 2007-10-05 | 2016-07-18 | 젠자임 코포레이션 | 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법 |
| WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| WO2010014554A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| US8309593B2 (en) | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
-
2005
- 2005-11-09 CA CA002586761A patent/CA2586761A1/en active Pending
- 2005-11-09 US US11/667,224 patent/US8003617B2/en not_active Expired - Fee Related
- 2005-11-09 WO PCT/US2005/040596 patent/WO2006053043A2/en not_active Ceased
- 2005-11-09 JP JP2007541294A patent/JP2008519840A/ja not_active Withdrawn
- 2005-11-09 EP EP05826118.1A patent/EP1811991B1/en not_active Expired - Lifetime
- 2005-11-09 BR BRPI0517701A patent/BRPI0517701A8/pt not_active Application Discontinuation
-
2011
- 2011-07-29 US US13/193,990 patent/US20120022126A1/en not_active Abandoned
-
2012
- 2012-10-10 JP JP2012225142A patent/JP2013032377A/ja active Pending
-
2014
- 2014-07-28 JP JP2014152732A patent/JP5837657B2/ja not_active Expired - Fee Related
- 2014-08-20 US US14/464,432 patent/US9532976B2/en not_active Expired - Fee Related
-
2015
- 2015-07-03 JP JP2015134366A patent/JP2015193638A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008519840A5 (enExample) | ||
| CN1248683C (zh) | 二肽基肽酶iv抑制剂在制备治疗2型糖尿病的药物中的用途 | |
| CN1443068A (zh) | 用于治疗糖尿病的二肽基肽酶iv抑制剂和其它抗糖尿病药剂的组合用药物 | |
| JP2008523126A5 (enExample) | ||
| JP2005112864A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| JP2013006854A5 (enExample) | ||
| JP2010530881A5 (enExample) | ||
| JP2014240402A5 (enExample) | ||
| AU2002244860A1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | |
| CN1354658A (zh) | 化合物作为抗菌剂的新用途 | |
| JP2007508360A5 (enExample) | ||
| JP2007533722A5 (enExample) | ||
| JP2005517677A5 (enExample) | ||
| JP2005526696A5 (enExample) | ||
| JP2004315496A5 (enExample) | ||
| JP2005532397A5 (enExample) | ||
| JP2008500378A5 (enExample) | ||
| JP2004538314A5 (enExample) | ||
| JP2008545627A5 (enExample) | ||
| CN1162152C (zh) | 糖尿病治疗剂 | |
| JP2007513888A5 (enExample) | ||
| JP2006524677A5 (enExample) | ||
| JP2007536318A5 (enExample) | ||
| US7642274B2 (en) | Inhibitor of pain threshold decrease |